vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $182.4M, roughly 1.1× Climb Global Solutions, Inc.). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs 1.1%, a 0.7% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 4.9%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 0.8%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
CLMB vs VREX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $209.6M |
| Net Profit | $3.3M | $2.3M |
| Gross Margin | 14.5% | 33.3% |
| Operating Margin | 2.1% | 7.3% |
| Net Margin | 1.8% | 1.1% |
| Revenue YoY | 32.1% | 4.9% |
| Net Profit YoY | -9.5% | 866.7% |
| EPS (diluted) | $0.18 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | $209.6M | ||
| Q4 25 | $193.8M | $228.9M | ||
| Q3 25 | $161.3M | $203.0M | ||
| Q2 25 | $159.3M | $212.9M | ||
| Q1 25 | $138.0M | $199.8M | ||
| Q4 24 | $161.8M | — | ||
| Q3 24 | $119.3M | $205.7M | ||
| Q2 24 | $92.1M | $209.1M |
| Q1 26 | $3.3M | $2.3M | ||
| Q4 25 | $7.0M | $12.2M | ||
| Q3 25 | $4.7M | $-89.1M | ||
| Q2 25 | $6.0M | $6.9M | ||
| Q1 25 | $3.7M | $-300.0K | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $5.5M | $-51.1M | ||
| Q2 24 | $3.4M | $1.4M |
| Q1 26 | 14.5% | 33.3% | ||
| Q4 25 | 15.4% | 34.0% | ||
| Q3 25 | 15.9% | 33.3% | ||
| Q2 25 | 16.5% | 36.0% | ||
| Q1 25 | 16.9% | 34.3% | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.3% | 32.6% | ||
| Q2 24 | 20.2% | 32.0% |
| Q1 26 | 2.1% | 7.3% | ||
| Q4 25 | 4.9% | 8.6% | ||
| Q3 25 | 4.3% | -39.8% | ||
| Q2 25 | 5.0% | 10.4% | ||
| Q1 25 | 3.5% | 5.6% | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 7.1% | 5.3% | ||
| Q2 24 | 4.6% | 4.4% |
| Q1 26 | 1.8% | 1.1% | ||
| Q4 25 | 3.6% | 5.3% | ||
| Q3 25 | 2.9% | -43.9% | ||
| Q2 25 | 3.7% | 3.2% | ||
| Q1 25 | 2.7% | -0.2% | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.6% | -24.8% | ||
| Q2 24 | 3.7% | 0.7% |
| Q1 26 | $0.18 | $0.05 | ||
| Q4 25 | $1.51 | $0.29 | ||
| Q3 25 | $1.02 | $-2.15 | ||
| Q2 25 | $1.30 | $0.17 | ||
| Q1 25 | $0.81 | $-0.01 | ||
| Q4 24 | $1.52 | — | ||
| Q3 24 | $1.19 | $-1.25 | ||
| Q2 24 | $0.75 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $125.6M |
| Total DebtLower is stronger | — | $367.6M |
| Stockholders' EquityBook value | $118.4M | $476.9M |
| Total Assets | $458.8M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | $125.6M | ||
| Q4 25 | $36.6M | $155.1M | ||
| Q3 25 | $49.8M | $152.6M | ||
| Q2 25 | $28.6M | $223.0M | ||
| Q1 25 | $32.5M | $212.6M | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $22.1M | $200.5M | ||
| Q2 24 | $48.4M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | $118.4M | $476.9M | ||
| Q4 25 | $116.6M | $472.6M | ||
| Q3 25 | $109.3M | $455.3M | ||
| Q2 25 | $105.2M | $549.7M | ||
| Q1 25 | $95.6M | $540.2M | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $87.7M | $529.1M | ||
| Q2 24 | $79.8M | $581.2M |
| Q1 26 | $458.8M | $1.1B | ||
| Q4 25 | $460.2M | $1.1B | ||
| Q3 25 | $376.1M | $1.1B | ||
| Q2 25 | $420.7M | $1.4B | ||
| Q1 25 | $370.1M | $1.3B | ||
| Q4 24 | $469.2M | — | ||
| Q3 24 | $371.9M | $1.2B | ||
| Q2 24 | $302.8M | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -12.8% |
| Capex IntensityCapex / Revenue | — | 5.1% |
| Cash ConversionOCF / Net Profit | — | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $-11.9M | $7.9M | ||
| Q3 25 | $22.2M | $7.7M | ||
| Q2 25 | $-2.2M | $16.6M | ||
| Q1 25 | $8.5M | $9.5M | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $-3.6M | $25.9M | ||
| Q2 24 | $7.3M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $19.9M | ||
| Q2 24 | — | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 9.7% | ||
| Q2 24 | — | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | — | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | -1.70× | 0.65× | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | 2.41× | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
